Pacific Biosciences of Californ Price Today
Pacific Biosciences of Californ
PACB
Healthcare
$924.43M
💰
Market Cap
0
💸
Price to Earnings
$-1.2
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
10 |
Strong Buy |
4 |
Hold |
6 |
Sell |
0 |
Strong Sell |
0 |
PACB Price Forecast Target
3.5 👉 20.0 +480%
PACB EPS Forecast
-1.2 👉 -0.9 +-29%
Financials
Profit Margin
-153 %
Revenue Growth
113.3 %
Dividend
$ 0
Held Percent
2.8% - Insiders
101.8% - Institutions
-4.6% - Public
Major Fund Holders
-
💰 ARK Investment Management, LLC $119.0M
-
💰 Vanguard Group Inc $92.4M
-
💰 Blackrock Inc. $85.0M
-
💰 Madrone Advisors, LLC $60.7M
-
💰 Sumitomo Mitsui Trust Holdings, Inc. $45.5M
Stock Ideas
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
David Tepper Portfolio
David Tepper is a renowned billionaire investor, widely known for his incredible success during the 2009 financial crisis where he made a staggering $4 billion. His financial prowess has earned him the distinction of being the 258th richest individ…
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
Larry Robbins Portfolio
Larry Robbins is a successful hedge fund manager who founded Glenview Capital in 2001 after working as a trader at Omega Advisors. His portfolio strategy has led to impressive returns, with Glenview Capital returning 301% after fees and expenses bet…📮FAQ
Some Frequently Asked Questions.
The Pacific Biosciences of Californ industry is Medical Devices
The Pacific Biosciences of Californ sector is Healthcare
The Pacific Biosciences of Californ forecasted predicted Price to Earnings PE ratio is -4.0
The Pacific Biosciences of Californ Price to Earnings PE ratio is 0
The Market Capitalization of Pacific Biosciences of Californ is $924.43M
There are total of 266435272 float shares with 101.8% held by Institutions and 2.8% held by insiders
The MPacific Biosciences of Californ forecasted Earnings per Share EPS is $-0.9
The Pacific Biosciences of Californ Earnings per Share EPS is -1.2
The Pacific Biosciences of Californ company has $0 gross profits with -153 profit margins
The Pacific Biosciences of Californ Earnings Growth is 0% with 0% quarterly earnings growth
The Pacific Biosciences of Californ Revenue is $200520992 with 1.133 revenue growth
The price target for Pacific Biosciences of Californ stock is $20.0 for the high target and $6.5 for the low target
The consensus analyst recommendations for Pacific Biosciences of Californ is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Pacific Biosciences of Californ is Buy, with the following breakdown:
- Buy: 10
- Strong Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 0
The Beta of Pacific Biosciences of Californ is 1.9
The dividend of Pacific Biosciences of Californ is $0
The dividend yield of Pacific Biosciences of Californ is 0%
The biggest institutional and mutual fund holders of Pacific Biosciences of Californ stock are
- ARK Investment Management, LLC
- Vanguard Group Inc
- Blackrock Inc.
- Madrone Advisors, LLC
The Pacific Biosciences of Californ ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0